Therapies and Preventive Strategies for Recurrent Clostridium Difficile Infections
EP. 1: Defining Traditional Risk Factors for Developing C. Diff Infection
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.
EP. 2: Recurrent CDI: Risk Factors and Outcomes
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.
EP. 3: Impact of Recurrent CDI on Patients and the Healthcare System
ByNeil D. Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.
EP. 4: Identifying Treatment Goals for Recurrent CDI
ByNeil D. Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.
EP. 5: Treatment Guidelines and Recommendations for C. Diff Infection
ByNeil D. Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.
EP. 6: Payer Perspectives on Coverage Criteria for Clostridium Difficile Treatments
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.
EP. 7: Practical Considerations for Fidaxomicin Use in Recurrent CDI
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.
EP. 8: Defining Value in Recurrent CDI
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.
A brief review of the role of bezlotoxumab therapy for patients at high risk for clostridium difficile infection recurrence.
EP. 10: Payer Perspectives on Risk Stratification for CDI Recurrence
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.
EP. 11: Challenges in the Management of C. Diff Infection
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Kevin U. Stephens, Sr, JD, MD ,Jessica Allegretti, MD, MPH ,Karina Abdallah, PharmD Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.
EP. 12: An Overview of Fecal Microbiota Transplant Use in C. Diff Infection
ByNeil Minkoff, MD,Jessica Allegretti, MD, MPH ,Dale N. Gerding, MD ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.
EP. 13: Barriers to Use of Fecal Microbiota Transplant in C. Diff Infection
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.
EP. 14: C. Diff Infection: Patient Access to Fecal Microbiota Transplant
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.
EP. 15: Evolving Medical Policies and Unmet Needs in C. Diff Infection Management
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.
EP. 16: Looking Toward the Future: Management of C. Diff Infection
ByNeil Minkoff, MD,Dale N. Gerding, MD ,Jessica Allegretti, MD, MPH ,Kevin U. Stephens, Sr, JD, MD ,Karina Abdallah, PharmD Closing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.
